Literature DB >> 31665429

DrugCombDB: a comprehensive database of drug combinations toward the discovery of combinatorial therapy.

Hui Liu1, Wenhao Zhang1, Bo Zou2, Jinxian Wang2, Yuanyuan Deng2, Lei Deng2,3.   

Abstract

Drug combinations have demonstrated high efficacy and low adverse side effects compared to single drug administration in cancer therapies and thus have drawn intensive attention from researchers and pharmaceutical enterprises. Due to the rapid development of high-throughput screening (HTS), the number of drug combination datasets available has increased tremendously in recent years. Therefore, there is an urgent need for a comprehensive database that is crucial to both experimental and computational screening of synergistic drug combinations. In this paper, we present DrugCombDB, a comprehensive database devoted to the curation of drug combinations from various data sources: (i) HTS assays of drug combinations; (ii) manual curations from the literature; and (iii) FDA Orange Book and external databases. Specifically, DrugCombDB includes 448 555 drug combinations derived from HTS assays, covering 2887 unique drugs and 124 human cancer cell lines. In particular, DrugCombDB has more than 6000 000 quantitative dose responses from which we computed multiple synergy scores to determine the overall synergistic or antagonistic effects of drug combinations. In addition to the combinations extracted from existing databases, we manually curated 457 drug combinations from thousands of PubMed publications. To benefit the further experimental validation and development of computational models, multiple datasets that are ready to train prediction models for classification and regression analysis were constructed and other significant related data were gathered. A website with a user-friendly graphical visualization has been developed for users to access the wealth of data and download prebuilt datasets. Our database is available at http://drugcombdb.denglab.org/.
© The Author(s) 2019. Published by Oxford University Press on behalf of Nucleic Acids Research.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31665429      PMCID: PMC7145671          DOI: 10.1093/nar/gkz1007

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  41 in total

Review 1.  The efficiency of multi-target drugs: the network approach might help drug design.

Authors:  Péter Csermely; Vilmos Agoston; Sándor Pongor
Journal:  Trends Pharmacol Sci       Date:  2005-04       Impact factor: 14.819

2.  SynLethDB: synthetic lethality database toward discovery of selective and sensitive anticancer drug targets.

Authors:  Jing Guo; Hui Liu; Jie Zheng
Journal:  Nucleic Acids Res       Date:  2015-10-29       Impact factor: 16.971

Review 3.  The search for synergy: a critical review from a response surface perspective.

Authors:  W R Greco; G Bravo; J C Parsons
Journal:  Pharmacol Rev       Date:  1995-06       Impact factor: 25.468

Review 4.  Tumour stem cells and drug resistance.

Authors:  Michael Dean; Tito Fojo; Susan Bates
Journal:  Nat Rev Cancer       Date:  2005-04       Impact factor: 60.716

5.  Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials.

Authors:  Ann Lin; Christopher J Giuliano; Ann Palladino; Kristen M John; Connor Abramowicz; Monet Lou Yuan; Erin L Sausville; Devon A Lukow; Luwei Liu; Alexander R Chait; Zachary C Galluzzo; Clara Tucker; Jason M Sheltzer
Journal:  Sci Transl Med       Date:  2019-09-11       Impact factor: 17.956

Review 6.  Cancer drug resistance: an evolving paradigm.

Authors:  Caitriona Holohan; Sandra Van Schaeybroeck; Daniel B Longley; Patrick G Johnston
Journal:  Nat Rev Cancer       Date:  2013-10       Impact factor: 60.716

7.  DrugBank 5.0: a major update to the DrugBank database for 2018.

Authors:  David S Wishart; Yannick D Feunang; An C Guo; Elvis J Lo; Ana Marcu; Jason R Grant; Tanvir Sajed; Daniel Johnson; Carin Li; Zinat Sayeeda; Nazanin Assempour; Ithayavani Iynkkaran; Yifeng Liu; Adam Maciejewski; Nicola Gale; Alex Wilson; Lucy Chin; Ryan Cummings; Diana Le; Allison Pon; Craig Knox; Michael Wilson
Journal:  Nucleic Acids Res       Date:  2018-01-04       Impact factor: 16.971

8.  Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de-differentiated state.

Authors:  Mohammad Fallahi-Sichani; Verena Becker; Benjamin Izar; Gregory J Baker; Jia-Ren Lin; Sarah A Boswell; Parin Shah; Asaf Rotem; Levi A Garraway; Peter K Sorger
Journal:  Mol Syst Biol       Date:  2017-01-09       Impact factor: 11.429

9.  Drug combination sensitivity scoring facilitates the discovery of synergistic and efficacious drug combinations in cancer.

Authors:  Alina Malyutina; Muntasir Mamun Majumder; Wenyu Wang; Alberto Pessia; Caroline A Heckman; Jing Tang
Journal:  PLoS Comput Biol       Date:  2019-05-20       Impact factor: 4.475

10.  Target inhibition networks: predicting selective combinations of druggable targets to block cancer survival pathways.

Authors:  Jing Tang; Leena Karhinen; Tao Xu; Agnieszka Szwajda; Bhagwan Yadav; Krister Wennerberg; Tero Aittokallio
Journal:  PLoS Comput Biol       Date:  2013-09-12       Impact factor: 4.475

View more
  34 in total

1.  An In Silico Method for Predicting Drug Synergy Based on Multitask Learning.

Authors:  Xin Chen; Lingyun Luo; Cong Shen; Pingjian Ding; Jiawei Luo
Journal:  Interdiscip Sci       Date:  2021-02-21       Impact factor: 2.233

2.  Anticancer drug synergy prediction in understudied tissues using transfer learning.

Authors:  Yejin Kim; Shuyu Zheng; Jing Tang; Wenjin Jim Zheng; Zhao Li; Xiaoqian Jiang
Journal:  J Am Med Inform Assoc       Date:  2021-01-15       Impact factor: 4.497

3.  CellMiner Cross-Database (CellMinerCDB) version 1.2: Exploration of patient-derived cancer cell line pharmacogenomics.

Authors:  Augustin Luna; Fathi Elloumi; Sudhir Varma; Yanghsin Wang; Vinodh N Rajapakse; Mirit I Aladjem; Jacques Robert; Chris Sander; Yves Pommier; William C Reinhold
Journal:  Nucleic Acids Res       Date:  2021-01-08       Impact factor: 16.971

4.  bayesynergy: flexible Bayesian modelling of synergistic interaction effects in in vitro drug combination experiments.

Authors:  Leiv Rønneberg; Andrea Cremaschi; Robert Hanes; Jorrit M Enserink; Manuela Zucknick
Journal:  Brief Bioinform       Date:  2021-11-05       Impact factor: 11.622

Review 5.  Machine learning approaches for drug combination therapies.

Authors:  Betül Güvenç Paltun; Samuel Kaski; Hiroshi Mamitsuka
Journal:  Brief Bioinform       Date:  2021-11-05       Impact factor: 11.622

6.  Prediction of Synergistic Drug Combinations for Prostate Cancer by Transcriptomic and Network Characteristics.

Authors:  Shiqi Li; Fuhui Zhang; Xiuchan Xiao; Yanzhi Guo; Zhining Wen; Menglong Li; Xuemei Pu
Journal:  Front Pharmacol       Date:  2021-04-12       Impact factor: 5.810

7.  Machine learning methods, databases and tools for drug combination prediction.

Authors:  Lianlian Wu; Yuqi Wen; Dongjin Leng; Qinglong Zhang; Chong Dai; Zhongming Wang; Ziqi Liu; Bowei Yan; Yixin Zhang; Jing Wang; Song He; Xiaochen Bo
Journal:  Brief Bioinform       Date:  2022-01-17       Impact factor: 11.622

8.  Genome-Wide Differential Methylation Profiles from Two Terpene-Rich Medicinal Plant Extracts Administered in Osteoarthritis Rats.

Authors:  Younhee Shin; Sathiyamoorthy Subramaniyam; Jin-Mi Chun; Ji-Hyeon Jeon; Ji-Man Hong; Hojin Jung; Boseok Seong; Chul Kim
Journal:  Plants (Basel)       Date:  2021-06-02

9.  GraphSynergy: a network-inspired deep learning model for anticancer drug combination prediction.

Authors:  Jiannan Yang; Zhongzhi Xu; William Ka Kei Wu; Qian Chu; Qingpeng Zhang
Journal:  J Am Med Inform Assoc       Date:  2021-10-12       Impact factor: 7.942

10.  Integrative resource for network-based investigation of COVID-19 combinatorial drug repositioning and mechanism of action.

Authors:  A K M Azad; Shadma Fatima; Alexander Capraro; Shafagh A Waters; Fatemeh Vafaee
Journal:  Patterns (N Y)       Date:  2021-07-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.